Healthcare
Merck & Co., Inc.(MRK)
Live Price
Offline$113.87
-1.36% today
1Y Change
+50.12%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $277.03B
- Revenue Growth
- +1.3%
- EPS Growth
- +7.7%
- Dividend Yield
- 3.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Merck & Co., Inc. (MRK) is a Healthcare stock with a market cap of $277.03B and listed on NYSE. The stock last traded around $113.87 and up 50.1% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +1.3%, EPS growth of +7.7%, a dividend yield of 3.0%. What stands out right now is revenue +1.3%, EPS +7.7%, free cash flow -31.7% with operating margin 28.8% and ROIC 13.1%. The dividend matters to the case here, with a current yield around 3.0%. Valuation already assumes a fairly strong business story at P/E 31.0 and price/sales 4.2. Stock Foundry combines MRK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.3% vs +7.6% peer median
Operating Margin
Above sector median
+28.8% vs +19.4% peer median
P/E
Below sector median
31.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q2 2026 was reported on Apr 30, 2026 with an EPS surprise of +12.9%.
The operating story is still moving forward
Revenue is running at +1.3% and EPS at +7.7%, with operating margin around 28.8%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 3, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.0% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 Apr 30, 2026 | +12.9% | +2.7% | +2.9% | +8.7% |
Q1 2026 Feb 16, 2026 | +94.6% | +0.1% | +1.9% | -4.7% |
Q1 2026 Feb 3, 2026 | +1.5% | +2.1% | +1.1% | +3.8% |
Benchmark Edge
MRK vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MRK
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MRK Max Drawdown
-11.90%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MRK and SPY.
Company Overview
Merck & Co., Inc.
New York Stock Exchange
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
- Leadership
- Robert Davis
- IPO Date
- Jan 13, 1978
- Employees
- 73.0k
- Street Address
- 126 East Lincoln Avenue
- Mailing
- Rahway, NJ, 07065
- Region
- Rahway, NJ, US
- Reporting Currency
- USD
- Investor Line
- 908 740 4000
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 31.0
- EV/EBITDA
- 18.3
- Price/Sales
- 4.2
- Price/Book
- 5.3
Growth
- Revenue
- +1.3%
- EPS
- +7.7%
- Free Cash Flow
- -31.7%
Profitability
- Gross Margin
- 82.4%
- Operating Margin
- 28.8%
- Net Margin
- 13.6%
- ROE
- 17.7%
- ROIC
- 13.1%
Balance Sheet
- Debt/Equity
- 0.96
- Current Ratio
- 1.54
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.